Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 266

Similar articles for PubMed (Select 19679402)

1.

In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.

Dahle J, Krogh C, Melhus KB, Borrebaek J, Larsen RH, Kvinnsland Y.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):886-95. doi: 10.1016/j.ijrobp.2009.04.062. Epub 2009 Aug 11.

PMID:
19679402
2.

Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.

Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH.

Nucl Med Biol. 2006 Feb;33(2):271-9.

PMID:
16546683
3.

Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.

Dahle J, Bruland OS, Larsen RH.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):186-92. doi: 10.1016/j.ijrobp.2008.05.029.

PMID:
18722269
4.

Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.

Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH.

Blood. 2007 Sep 15;110(6):2049-56. Epub 2007 May 29.

5.

Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.

Heyerdahl H, Krogh C, Borrebæk J, Larsen Å, Dahle J.

Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):563-70. doi: 10.1016/j.ijrobp.2010.08.038.

PMID:
21195878
6.

Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.

Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, Larsen RH.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):93-102. doi: 10.1007/s00259-009-1197-7. Epub .

PMID:
19593562
7.

In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.

Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke HR.

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1443-52. doi: 10.1007/s00259-009-1120-2. Epub 2009 Apr 7.

PMID:
19350237
8.
9.

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.

J Nucl Med. 2005 Nov;46(11):1907-15.

10.
11.

Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.

Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.

J Nucl Med. 2006 Aug;47(8):1342-50.

12.

A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.

Lindén O, Kurkus J, Garkavij M, Cavallin-Ståhl E, Ljungberg M, Nilsson R, Ohlsson T, Sandberg B, Strand SE, Tennvall J.

Cancer Biother Radiopharm. 2005 Aug;20(4):457-66.

PMID:
16114994
13.

Radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Witzig TE.

Best Pract Res Clin Haematol. 2006;19(4):655-68. Review.

PMID:
16997175
14.

Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3938S-44S.

15.

[In vitro cytotoxicity of 131I-Rituximab against B-cell lymphoma cells].

Wei L, Luo RC, Zhang JY, Yan X, Lü CW.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Jan;29(1):40-3. Chinese.

16.

An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.

Thakral P, Singla S, Yadav MP, Vasisht A, Sharma A, Gupta SK, Bal CS; Snehlata, Malhotra A.

Indian J Med Res. 2014 Apr;139(4):544-54.

17.

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.

Gholipour N, Jalilian AR, Khalaj A, Johari-Daha F, Yavari K, Sabzevari O, Khanchi AR, Akhlaghi M.

Daru. 2014 Jul 29;22:58. doi: 10.1186/2008-2231-22-58.

18.

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM.

Blood. 2008 Aug 1;112(3):830-5. doi: 10.1182/blood-2008-01-132142. Epub 2008 May 23.

19.

Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.

Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J.

PLoS One. 2012;7(8):e42345. doi: 10.1371/journal.pone.0042345. Epub 2012 Aug 3.

20.

Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.

Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL.

Radiat Res. 1992 May;130(2):220-6.

PMID:
1574578
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk